Claire Mathiot

Institut Curie — France

Medicine · Health Sciences

50h-index13.8kcitations199works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(89), Protein Degradation and Inhibitors(35), Peptidase Inhibition and Analysis(30), Cancer Treatment and Pharmacology(26), Cancer Cells and Metastasis(23)

Publications199 total

Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients
Blood·2021· 1 cited
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
The Lancet·2019· 925 citedOpen Access
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma
Leukemia·2019· 42 citedOpen Access
Light Chain Escape in Multiple Myeloma
Blood·2018· 11 cited
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
Blood·2018· 65 citedOpen Access
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma
Annals of Hematology·2018
A Multicenter Open Label Phase II Study of Pomalidomide, Cyclophosphamide and Dexamethasone in Relapse Multiple Myeloma Patients Initially Treated with Lenalidomide, Bortezomib and Dexamethasone
Blood·2017· 5 cited
Activité de recherche clinique académique des investigateurs du réseau des Groupes coopérateurs en oncologie (GCO) : bilan et perspectives
Bulletin du Cancer·2017· 2 cited
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
New England Journal of Medicine·2017· 1.2k citedOpen Access
Characteristics of chronic lymphocytic leukemia in Senegal
BMC Hematology·2016· 25 citedOpen Access
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma
Annals of Oncology·2016· 11 citedOpen Access
Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)
Blood·2015· 126 cited
Salvage Therapy Post Pomalidomide-Based Regimen in Relapsed/Refractory Myeloma
Blood·2015
Salvage Therapy Post Pomalidomide-Based Regimen in Relapsed/Refractory Myeloma
SPIRE - Sciences Po Institutional REpository·2015
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results
Blood·2015· 100 cited
Hevylite® to Monitor Hypogammaglobulinemia, a Predictor of Response to Therapy in Multiple Myeloma
Blood·2014· 1 cited
Long-Term Exposure to Pomalidomide-Dexamethasone in Pts with Refractory Myeloma
Blood·2014· 1 cited
Hevylite® to Monitor Response to Therapy in Multiple Myeloma
Blood·2014· 2 cited
Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial
Haematologica·2014· 36 citedOpen Access
IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma
Cancer·2014· 36 cited
page 1 of 10Next →

Frequent Co-authors

Hervé Avet‐Loiseau(29), Thierry Façon(28), Philippe Moreau(28), Michel Attal(26), Cyrille Hulin(22), Gérald Marit(20), Denis Caillot(19), Laurent Garderet(16), Jean‐Luc Harousseau(15), Murielle Roussel(12), Lotfi Benboubker(12), Brigitte Kolb(12), Brigitte Pegourié(11), Xavier Leleu(10), Laurent Voillat(10), Margaret Macro(9), Mauricette Michallet(9), Chantal Doyen(9), Anne‐Marie Stoppa(8), Jean‐Yves Pierga(8)